Affordable Access

Access to the full text

Relaxin Positively Influences Ischemia—Reperfusion Injury in Solid Organ Transplantation: A Comprehensive Review

Authors
  • Jakubauskiene, Lina1,
  • Jakubauskas, Matas1,
  • Leber, Bettina1
  • Strupas, Kestutis
  • Stiegler, Philipp1
  • Schemmer, Peter1
  • 1 (P.S.)
Type
Published Article
Journal
International Journal of Molecular Sciences
Publisher
MDPI AG
Publication Date
Jan 17, 2020
Volume
21
Issue
2
Identifiers
DOI: 10.3390/ijms21020631
PMID: 31963613
PMCID: PMC7013572
Source
PubMed Central
Keywords
License
Green

Abstract

In recent decades, solid organ transplantation (SOT) has increased the survival and quality of life for patients with end-stage organ failure by providing a potentially long-term treatment option. Although the availability of organs for transplantation has increased throughout the years, the demand greatly outweighs the supply. One possible solution for this problem is to extend the potential donor pool by using extended criteria donors. However, organs from such donors are more prone to ischemia reperfusion injury (IRI) resulting in higher rates of delayed graft function, acute and chronic graft rejection and worse overall SOT outcomes. This can be overcome by further investigating donor preconditioning strategies, graft perfusion and storage and by finding novel therapeutic agents that could reduce IRI. relaxin (RLX) is a peptide hormone with antifibrotic, antioxidant, anti-inflammatory and cytoprotective properties. The main research until now focused on heart failure; however, several preclinical studies showed its potentials for reducing IRI in SOT. The aim of this comprehensive review is to overview currently available literature on the possible role of RLX in reducing IRI and its positive impact on SOT.

Report this publication

Statistics

Seen <100 times